VISTAGEN THERAPEUTICS, INC. Stock or Unit Option Plan Expense
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Stock or Unit Option Plan Expense of $15.50 thousand for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2015-08-14
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for the quarter ending 2015-06-30 was $15.50K, a 74.80% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for the quarter ending 2014-12-31 was $30.00K, a 76.36% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for the quarter ending 2014-09-30 was $64.60K, a 9.31% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for the quarter ending 2014-06-30 was $61.50K, a 13.26% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for fiscal 2014 was $296.90K, a 22.53% increase from fiscal 2013.
- VISTAGEN THERAPEUTICS, INC. stock or unit option plan expense for fiscal 2013 was $242.30K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2015-06-30 | $15.50K 10-Q · filed 2015-08-14 | |||
| 2014-12-31 | $30.00K 10-Q · filed 2015-02-17 | $94.60K derived: sum of 2 quarters · filed 2015-02-17 | $156.10K 10-Q · filed 2015-02-17 | $212.70K derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-09-30 | $64.60K 10-Q · filed 2014-11-19 | $126.10K 10-Q · filed 2014-11-19 | $182.70K derived: sum of 3 quarters · filed 2015-08-14 | $309.60K derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-06-30 | $61.50K 10-Q · filed 2015-08-14 | $118.10K derived: sum of 2 quarters · filed 2015-08-14 | $245.00K derived: sum of 3 quarters · filed 2015-08-14 | $304.10K derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-03-31 | $56.60K derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | $183.50K derived: sum of 2 quarters · filed 2015-02-17 | $242.60K derived: sum of 3 quarters · filed 2015-02-17 | $296.90K 10-K · filed 2014-06-25 |
| 2013-12-31 | $126.90K 10-Q · filed 2015-02-17 | $186.00K derived: sum of 2 quarters · filed 2015-02-17 | $240.30K 10-Q · filed 2015-02-17 | -$184.20K derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-09-30 | $59.10K 10-Q · filed 2014-11-19 | $113.40K 10-Q · filed 2014-11-19 | -$311.10K derived: sum of 3 quarters · filed 2014-11-19 | $263.60K derived: sum of 4 quarters · filed 2014-11-19 |
| 2013-06-30 | $54.30K 10-Q · filed 2014-08-12 | -$370.20K derived: sum of 2 quarters · filed 2014-08-12 | $204.50K derived: sum of 3 quarters · filed 2014-08-12 | |
| 2013-03-31 | -$424.50K derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | $150.20K derived: sum of 2 quarters · filed 2014-06-25 | $242.30K 10-K · filed 2014-06-25 | |
| 2012-12-31 | $574.70K 10-Q · filed 2014-02-14 | $666.80K 10-Q · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |